Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results

References

• Ding X, Patel M, Chan -C-C. Molecular pathology of age-related macular degeneration. Prog Retin Eye Res. 2009;28(1):1–18. doi:10.1016/j.preteyeres.2008.10.001
   PubMed Web of Science ®Google Scholar
• Cheung LK, Eaton A. Age-related macular degeneration. Pharmacotherapy. 2013;33(8):838–855. doi:10.1002/phar.1264
   PubMed Web of Science ®Google Scholar
• Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol. 2009;20(3):158–165. doi:10.1097/ICU.0b013e32832d25b3
   PubMed Web of Science ®Google Scholar
• Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res. 2008;27(4):372–390. doi:10.1016/j.preteyeres.2008.05.002
   PubMed Web of Science ®Google Scholar
• Shirley M. Faricimab: first approval. Drugs. 2022;82(7):825–830. doi:10.1007/s40265-022-01713-3
   PubMed Web of Science ®Google Scholar
• Vabysmo prescribing information. Available from: https://www.gene.com/download/pdf/vabysmo_prescribing.pdf. Accessed August 20, 2022.
   Google Scholar
• Flaxel CJ, Adelman RA, Bailey ST, et al. Age-related macular degeneration Preferred Practice Pattern®. Ophthalmology. 2020;127(1):P1–P65. doi:10.1016/j.ophtha.2019.09.024
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Chong V, Loewenstein A, et al. Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol. 2014;98(9):1144–1167. doi:10.1136/bjophthalmol-2014-305702
   PubMed Web of Science ®Google Scholar
• Prenner JL, Halperin LS, Rycroft C, et al. Disease burden in the treatment of age-related macular degeneration: findings from a time-and-motion study. Am J Ophthalmol. 2015;160(4):725–731.e1. doi:10.1016/j.ajo.2015.06.023
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Lieske HB, et al. Societal costs associated with neovascular age-related macular degeneration in the United States. Retina. 2016;36(2):285–298. doi:10.1097/IAE.0000000000000717
   PubMed Web of Science ®Google Scholar
• Singh RP, Stone TW, eds. 2008 Global Trends in Retina Survey. Chicago, IL: American Society of Retina Specialists; 2018.
   Google Scholar
• Smithwick E, Stewart MW. Designed ankyrin repeat proteins: a look at their evolving use in medicine with a focus on the treatment of chorioretinal vascular disorders. Antiinflamm Antiallergy Agents Med Chem. 2017;16(1):33–45. doi:10.2174/1871523016666170502115816
   PubMedGoogle Scholar
• Plückthun A. Designed ankyrin repeat proteins (DARPins): binding proteins for research, diagnostics, and therapy. Annu Rev Pharmacol Toxicol. 2015;55(1):489–511. doi:10.1146/annurev-pharmtox-010611-134654
   PubMed Web of Science ®Google Scholar
• Campochiaro PA, Channa R, Berger BB, et al. Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. Am J Ophthalmol. 2013;155(4):697. doi:10.1016/j.ajo.2012.09.032
   PubMed Web of Science ®Google Scholar
• Krohne TU, Liu Z, Holz FG, Meyer CH. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am J Ophthalmol. 2012;154(4):682–686.e2. doi:10.1016/j.ajo.2012.03.047
   PubMed Web of Science ®Google Scholar
• Khurana RN, Kunimoto D, Yoon YH, et al. Two-year results of the phase 3 randomized controlled study of abicipar in neovascular age-related macular degeneration. Ophthalmology. 2020;128(7):1027–1038.
   PubMed Web of Science ®Google Scholar
• Kunimoto D, Yoon YH, Wykoff CC, et al. Efficacy and safety of abicipar in neovascular age-related macular degeneration: 52-week results of phase 3 randomized controlled study. Ophthalmology. 2020;127(10):1331–1344. doi:10.1016/j.ophtha.2020.03.035
   PubMed Web of Science ®Google Scholar
• Rodrigues GA, Mason M, Christie L-A, et al. Functional characterization of abicipar-pegol, an anti-VEGF DARPin therapeutic that potently inhibits angiogenesis and vascular permeability. Invest Ophthalmol Vis Sci. 2018;59(15):5836–5846. doi:10.1167/iovs.18-25307
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol. 2006;124(11):1532–1542. doi:10.1001/archopht.124.11.1532
   PubMed Web of Science ®Google Scholar
• Chong DY, Anand R, Williams PD, et al. Characterization of sterile intraocular inflammatory responses after intravitreal bevacizumab injection. Retina. 2010;30(9):1432–1440. doi:10.1097/IAE.0b013e3181dc04da
   PubMed Web of Science ®Google Scholar
• Verthelyi D, Wang V, Vij N. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS One. 2010;5(12):e15252. doi:10.1371/journal.pone.0015252
   PubMed Web of Science ®Google Scholar
• Holley CK, Dobrovolskaia MA. Innate immunity modulating impurities and the immunotoxicity of nanobiotechnology-based drug products. Molecules. 2021;26(23):7308. doi:10.3390/molecules26237308
   PubMed Web of Science ®Google Scholar
• Haile LA, Puig M, Polumuri SK, et al. In vivo effect of innate immune response modulating impurities on the skin milieu using a macaque model: impact on product immunogenicity. J Pharm Sci. 2017;106(3):751–760. doi:10.1016/j.xphs.2016.11.001
   PubMed Web of Science ®Google Scholar
• Spitzer MS, Ziemssen F, Bartz-Schmidt KU, et al. Treatment of age-related macular degeneration: focus on ranibizumab. Clin Ophthalmol. 2008;2(1):1–14. doi:10.2147/OPTH.S1959
   PubMedGoogle Scholar
• Greenberg JP, Belin P, Butler J, et al. Aflibercept-related sterile intraocular inflammation outcomes. Ophthalmol Retina. 2019;3(9):753–759. doi:10.1016/j.oret.2019.04.006
   PubMedGoogle Scholar
• Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013;2013:943409. doi:10.1155/2013/943409
   PubMed Web of Science ®Google Scholar
• Ness T, Feltgen N, Agostini H, et al. Toxic vitreitis outbreak after intravitreal injection. Retina. 2010;30(2):332–338. doi:10.1097/IAE.0b013e3181baf691
   PubMed Web of Science ®Google Scholar
• Palmer JM, Amoaku WM, Kamali F. Quality of bevacizumab compounded for intravitreal administration. Eye. 2013;27(9):1090–1097. doi:10.1038/eye.2013.139
   PubMed Web of Science ®Google Scholar
• Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci. 2011;52(2):1023–1034. doi:10.1167/iovs.10-6431
   PubMed Web of Science ®Google Scholar
• Holz FG, Oleksy P, Ricci F, Kaiser PK, Kiefer J, Schmitz-Valckenberg S; COLUMBUS-AMD Study Group. Efficacy and safety of biosimilar FYB201 compared with ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2022;129(1):54–63. doi:10.1016/j.ophtha.2021.04.031
   PubMed Web of Science ®Google Scholar
• Dugel PU, Koh A, Ogura Y; HAWK and HARRIER Study Investigators. HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration. Ophthalmology. 2020;127(1):72–84. doi:10.1016/j.ophtha.2019.04.017
   PubMed Web of Science ®Google Scholar
• Melo GB, Cruz NFSD, Emerson GG, et al. Critical analysis of techniques and materials used in devices, syringes, and needles used for intravitreal injections. Prog Retin Eye Res. 2021;80:100862. doi:10.1016/j.preteyeres.2020.100862
   PubMed Web of Science ®Google Scholar